Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs ResMed Inc. — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $2.13, while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and ResMed Inc. is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | RMD | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $92.70 | $293.73 |
52-Week Low | $1.46 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
